The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...
Doctors prescribe Evenity (romosozumab-aqqg) for treating postmenopausal osteoporosis. The drug falls under Medicare Part B coverage because a healthcare professional must administer the injection. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback